Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa: Phase 2 Randomized Controlled Masked Multicenter Clinical Trial (Skyline) Interim Safety Results

  • Video
  • Published 2022

Related

    See more